Abiraterone Acetate

SKU: orb1300972

Description

Abiraterone Acetate is a steroidal inhibitor of 17α-hydroxylase/C17,20-lyase (CYP17A1), blocking androgen synthesis. It is a key therapeutic agent for metastatic castration-resistant prostate cancer. Its efficacy has been validated in both in vitro enzymatic assays and in vivo clinical studies.

Research Area

Metabolism Research, Pharmacology & Drug Discovery

Key Properties

• CAS Number: 154229-18-2
• MW: 391.55
• Purity: 99.51% (May vary between batches)
• Formula: C₂₆H₃₃NO₂
• SMILES: C[C@@]12[C@]([C@]3([C@](CC1)([C@]4(C)C(=CC3)C[C@@H](OC(C)=O)CC4)[H])[H])(CC=C2C=5C=CC=NC5)[H]
• Target: Cytochromes P450
• Solubility: DMSO:9.61 mg/mL (24.54 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:1 mg/mL (2.55 mM)

Bioactivity

• Target IC50:
  CYP17:72 nM
• In Vivo:
  Abiraterone inhibits the in vitro proliferation and androgen receptor (AR)-regulated gene expression of AR-positive prostate cancer cells, potentially due to its AR antagonistic effects beyond steroidogenesis inhibition. It blocks the enzyme 3β-hydroxysteroid dehydrogenase (3βHSD), essential for synthesizing bioactive androgens, thereby inhibiting DHT synthesis and androgen receptor responses. Abiraterone uniquely demonstrates a favorable complex formation with heme iron only in SM1. It inhibits CYP17A1, blocking androgen synthesis, and prevents the conversion of DHEA to Δ4-androstenedione and Δ5-androstenediol to testosterone. In rat testicular microsomes, abiraterone inhibits C17,20-lyase with an IC50 of 5.8 nM, significantly reducing testosterone secretion by 48% and correspondingly increasing LH concentration by 192%.
• In Vitro:
  In rodent models, intraperitoneal administration of Abiraterone rapidly undergoes deacetylation. Administered as its acetate prodrug (CB7630), it suppresses circulating testosterone to undetectable levels and significantly reduces the weight of androgen-sensitive organs. Abiraterone is well-tolerated, with an average elimination half-life of 27.6 hours, permitting once-daily dosing. Preclinical studies using Abiraterone demonstrate a reduction in CYP17 downstream androgen production, leading to a decrease in the weight of the mouse ventral prostate, testes, and seminal vesicles.
• Cell Research:
  LNCaP and VCaP cells are seeded in 96-well plates and grown in CSS-supplemented phenol red-free or FBS-supplemented media for 7 days. Cells are treated with Abiraterone at 24 hours and 96 hours after plating and cell viability is determined on day 7 by adding CellTiter Glo and measuring luminescence. (Only for Reference)

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

CB 7630, CB7630, CB-7630, Cytochrome P450, CYPs, CYP17, Abiraterone, Abiraterone Acetate, Inhibitor, inhibit, Zytiga

Compound Identifiers

PubChem CID

9821849